Rapid Readout: Expert Perspectives on Multiple Sclerosis - Data from the 8th Joint ACTRIMS-ECTRIMS Meeting 2020 : Episode 11
Video
Ofatumumab vs Teriflunomide: Phase 3 ASCLEPIOS I/II Open-Label Extension Study
EP: 1.Ofatumumab vs Teriflunomide: ASCLEPIOS I/II RMS Trials
EP: 2.OLKIOS: Looking at Ofatumumab’s Continued Efficacy
EP: 3.OPTIMUM: Ponesimod Superiority in MRI-based Outcomes in RRMS
EP: 4.Rationale for Selected Dosing Regimen of Evobrutinib in Phase 3 Studies
EP: 5.Takeaways From ACTRIMS-ECTRIMS 2020 Meeting
EP: 6.Phase 3 ASCLEPIOS I/II Open-Label Extension Study: Ofatumumab vs Teriflunomide
EP: 7.OLKIOS Phase 3b Trial: Pivotal Endpoints and Potential Significance
EP: 8.OPTIMUM Phase 3 Trial: Ponesimod’s Cardiac Safety Data
EP: 9.Ozanimod Compared to Teriflunomide Utilizing Statistical Matching
EP: 10.Key Takeaways from the 8th ACTRIMS-ECTRIMS 2020 Meeting
Now Viewing
EP: 11.Ofatumumab vs Teriflunomide: Phase 3 ASCLEPIOS I/II Open-Label Extension Study
EP: 12.Chief Endpoints and Potential Significance: Phase 3b OLIKOS Trial
EP: 13.CLARITY Extension Trial: Disability Improvement With Cladribine
EP: 14.COVID-19 in MS Global Data-Sharing Initiative Anti-CD20 Therapy Results
EP: 15.Impact of Results From the COVID-19 in MS Global Data-Sharing Initiative
Related Videos
Related Content
